Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23589874 | 0.90 | FAAH (0.42) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL13328238 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL23589696 | 0.87 | FAAH (0.47) | KMT2AMEN1FAAHTSHRRECQL | |
| SCHEMBL23589952 | 0.87 | KMT2A (0.45) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL23589903 | 0.87 | FAAH (0.47) | KMT2AMEN1FAAHTSHRRECQL | |
| SCHEMBL23589698 | 0.87 | FAAH (0.47) | KMT2AMEN1FAAHTSHRRECQL | |
| SCHEMBL18319068 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL23471188 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL26156218 | 0.84 | HPGD (0.49) | SMN1; SMN2HTTHPGDCNR1KMT2A | |
| SCHEMBL24530494 | 0.83 | HPGD (0.48) | SMN1; SMN2HTTHPGDCNR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| WO-2019092618-A9 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | SMN1; SMN2 4789/4885HTT 3882/4885HPGD 7/4885 |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | SMN1; SMN2 3594/4885HTT 1631/4885HPGD 4678/4885 |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | SMN1; SMN2 4557/4885HTT 3043/4885HPGD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.